PMID- 28641096
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20220330
IS  - 2589-0646 (Electronic)
IS  - 2589-0646 (Linking)
VI  - 10
IP  - 4
DP  - 2017 Dec
TI  - Hematopoietic stem cell transplantation for sickle cell disease: The changing 
      landscape.
PG  - 259-266
LID - S1658-3876(17)30044-4 [pii]
LID - 10.1016/j.hemonc.2017.05.008 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only 
      curative therapy for sickle cell disease (SCD); however, its use is limited by 
      lack of suitable human leukocyte antigen (HLA)-matched donors and decreased 
      application in older patients with significant morbidity. Myeloablative, 
      HLA-identical sibling transplantation in children with SCD offers excellent 
      long-term survival, with overall and event-free survival rates of 95% and 92%, 
      respectively. However, the risk of graft-versus-host-disease, infections, 
      infertility, and other long-term transplant complications, further limits its 
      widespread use. Recent approaches using reduced intensity conditioning (RIC) are 
      associated with lower toxicity, allowing extension of this modality to children 
      and adults with significant morbidity; however, these approaches are also 
      associated with increased risk of graft failure. The optimal RIC regimen that 
      strikes the optimal balance between maximizing the rate of stable engraftment 
      while minimizing transplant-related morbidity and mortality is unknown. 
      Alternative donor transplants, most prominently, partial HLA-mismatched related 
      transplants (haploidentical), are being investigated with promising initial 
      results. This review will discuss long-term results of HLA-matched sibling HSCT 
      for SCD, and recent updates on HLA-matched unrelated donor and unrelated 
      umbilical cord blood HSCT for SCD.
CI  - Copyright (c) 2017 King Faisal Specialist Hospital & Research Centre. Published by 
      Elsevier B.V. All rights reserved.
FAU - Kassim, Adetola A
AU  - Kassim AA
AD  - Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry 
      Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical 
      Center, Nashville, TN, USA. Electronic address: adetola.kassim@vanderbilt.edu.
FAU - Sharma, Deva
AU  - Sharma D
AD  - Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Meharry 
      Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical 
      Center, Nashville, TN, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170615
PL  - Saudi Arabia
TA  - Hematol Oncol Stem Cell Ther
JT  - Hematology/oncology and stem cell therapy
JID - 101468532
SB  - IM
MH  - Allografts
MH  - Anemia, Sickle Cell/mortality/*therapy
MH  - Disease-Free Survival
MH  - Donor Selection/*methods
MH  - Graft vs Host Disease/mortality/prevention & control
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Infection Control
MH  - Infections/etiology/mortality
MH  - Infertility/mortality/prevention & control
MH  - Survival Rate
MH  - Transplantation Conditioning/*methods
OTO - NOTNLM
OT  - Chronic blood transfusion
OT  - Hematopoietic stem cell transplantation
OT  - Sickle cell anemia
EDAT- 2017/06/24 06:00
MHDA- 2018/07/25 06:00
CRDT- 2017/06/23 06:00
PHST- 2017/01/16 00:00 [received]
PHST- 2017/01/30 00:00 [accepted]
PHST- 2017/06/24 06:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
PHST- 2017/06/23 06:00 [entrez]
AID - S1658-3876(17)30044-4 [pii]
AID - 10.1016/j.hemonc.2017.05.008 [doi]
PST - ppublish
SO  - Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):259-266. doi: 
      10.1016/j.hemonc.2017.05.008. Epub 2017 Jun 15.